Last reviewed · How we verify
SR-exenatide
At a glance
| Generic name | SR-exenatide |
|---|---|
| Also known as | DA-3091 |
| Sponsor | Dong-A Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation (PHASE2)
- SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease (PHASE2)
- Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects (PHASE1)
- A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SR-exenatide CI brief — competitive landscape report
- SR-exenatide updates RSS · CI watch RSS
- Dong-A Pharmaceutical Co., Ltd. portfolio CI